All posts by imreal

ThriveAP & Prevea Health Are Proud to Partner for APP Transition to Practice Education


“ThriveAP is honored to partner with medical institutions, like Prevea Health, that recognize the pivotal role Advanced Practice Providers play in the successful delivery of care,” said Dr. Veronica Hill, DNP, CRNP, VP Programs & Content at ThriveAP.

ThriveAP is proud to announce our latest partnership with Prevea Health. Together, these leading organizations will empower advanced practice providers (APPs) to accelerate their skills in a clinical setting.

ThriveAP is a comprehensive evidence-based solution for APPs that partners with employers and fellowship programs to provide end-to-end education, practical skill development and support for clinicians as they transition to practice. The turnkey, competency-based curriculum of live, virtual courses helps healthcare employers accelerate APP application of clinical skills by translating topics covered in school to real-world practice.

“ThriveAP is honored to partner with medical institutions, like Prevea Health, that recognize the pivotal role Advanced Practice Providers play in the successful delivery of care,” said Dr. Veronica Hill, DNP, CRNP, VP Programs & Content at ThriveAP. “Leading employers acknowledge the need to invest in the development and success of their APPs. As a result, employers are dedicated to supporting the significant role these professionals play by increasing their investments in education programs.”

Prevea Health is a multi-specialty health care provider, based in Green Bay, Wis., with 100+ locations across Wisconsin. Prevea Health is dedicated to investing in the development of their APPs, empowering them to deliver the best possible care.

“The education and support of our Advanced Practice Providers team is critical to providing our patients the highest quality of care throughout Wisconsin,” said Amber Allen, Executive Director of Primary Care, Quality and Innovation at Prevea Health. “Providing access to ThriveAP is a way for us to ensure our Advanced Practice Providers have the tools they need to be successful.”

About Prevea Health

Founded in Green Bay, Wis. in 1996, Prevea Health is a health care organization that provides high-quality, primary and specialty health care in 80+ locations across Northern, Eastern and Western Wisconsin in clinic and hospital settings. It is partnered with six Hospital Sisters Health System (HSHS) hospitals across Wisconsin to provide patients a system of highly-coordinated care, close to home: HSHS St. Vincent Hospital and HSHS St. Mary’s Hospital Medical Center in Green Bay; HSHS St. Nicholas Hospital in Sheboygan; HSHS St. Clare Memorial Hospital in Oconto Falls; HSHS Sacred Heart Hospital in Eau Claire; and HSHS St. Joseph’s Hospital in Chippewa Falls. For more information, visit http://www.prevea.com.

About ThriveAP

Founded in 2012, ThriveAP is a transition to practice solution for Advanced Practice Providers and their employers throughout the nation. ThriveAP’s educational program helps facilitate the growing impact of APPs in the delivery of healthcare and is recognized for its quality, relevance, and convenience. The ThriveAP program blends interactive educational experiences, community, and support to improve provider productivity, proficiency, and confidence through real-world skill development. Learn more, ThriveAP.com

Share article on social media or email:

DuPont Announces 2022 Nomex® Innovation Award Winners for Design Ingenuity


SIOEN, Oxylus NYO is the first wildland gear with a particulate barrier to be introduced to the wildland firefighting market. Winner of a 2022 Nomex® Innovation Award.

“These awards recognize the ongoing commitment to technology, leadership and innovation of our Nomex® partners, the power of our joint collaboration and underscores the proven performance of Nomex® across a range of applications.”

DuPont Personal Protection recognized the latest in Nomex® design ingenuity during the 2022 Nomex® Innovation Awards at Interschutz, a leading trade fair for fire and rescue services, civil protection and safety and security sectors. The seventh annual award ceremony was held in Hannover, Germany on June 21, 2022, and highlighted collaboration between European Nomex® partners and DuPont in developing solutions made with Nomex® in applications that help provide enhanced end-user safety.

Alfons Held, Global Marketing Manager for Emergency Response, DuPont, announced the winners during a recognition ceremony.

“The Nomex® Innovation Awards spotlight product developments that help make a positive impact on worker safety,” Held said. “These awards recognize the ongoing commitment to technology, leadership and innovation of our Nomex® partners, the power of our joint collaboration and underscores the proven performance of Nomex® across a range of applications.”

The 2022 Nomex® Innovation Awards included four main categories, including a new category, Nomex® Xtreme Performance; in addition to Sustainability; Comfort; and Other Innovations.

Earlier this year, DuPont launched Nomex® Xtreme Performance—a product category offering ease of selection of innovative personal protective equipment (PPE) solutions for structural and nonstructural firefighting gear. Solutions in the new Nomex® Xtreme Performance category combine the superior benefits of DuPont™ Nomex®, DuPont™ Kevlar® and high-performance materials such as PBO, Nomex® Nano and Nomex® Nano Flex to help provide firefighters with superior thermal protection and moisture management, along with protection from heat, flame, chemicals, cuts and hazardous particulates.

This year’s category applications included structural firefighting and wildland firefighting.

Winners in the structural firefighting category included:

SCANTEX Crossfire, Outer layer built with DuPont™ Nomex® 3DP Plus and DuPont™ Kevlar®. This new outershell solution in the Nomex® Xtreme Performance category provides superior durability and comfort; built-in heat and flame resistance; and unmatched mechanical strength.

S-GARD, SWISSGARD 2.0, Outer layer built with DuPont™ Nomex® RSK, Inner layer built with DuPont™ Nomex® Comfort. This garment is optimized for greater mobility and enhanced comfort.

Winners in the wildland firefighting category included:

SIOEN, Oxylus NYO wildland firefighting gear, garment made of a three-layer laminate, built with DuPont™ Nomex® Comfort Ripstop, particulate barrier built with DuPont™ Nomex® Nano, Inner layer built with DuPont™ Nomex® Knit. This solution in the Nomex® Xtreme Performance category is the first wildland gear with a particulate barrier to be introduced to the wildland firefighting market.

Heinrich Vorndamme O.H.G., Fire Fox Twin, Outer layer built with DuPont™ Nomex® VRW. This gear is an innovative combination of layers designed to meet the requirements of both wildland firefighting and technical rescue. One layer of this solution can be worn by itself for wildland firefighting; the other layer can be worn by itself for technical rescue; and when both layers are worn together, it is a dual-purpose garment.

To learn more about Nomex® Xtreme Performance, visit nomex.com/xtremeperformance

About DuPont™ Nomex®

Tested and trusted for more than 50 years, DuPont™ Nomex® has inherent heat- and flame-resistant properties that help provide the performance and protection needed for emergency responders worldwide. As a critical component in flame-resistant personal protective apparel, Nomex® can be found in a range of firefighter applications, including turnout gear, stationwear, rescue gear and accessories. The unique combination of flame protection, durability and mobility helps firefighters get the most challenging jobs done safely.

About DuPont Personal Protection

From first responders to industrial workers, DuPont provides a wide range of personal protection solutions, including some of the most trusted and innovative brands in the industry, such as Kevlar®, Nomex®, Tyvek® and Tychem®, to meet your safety needs. More information can be found at personalprotection.dupont.com.

About DuPont Water & Protection

DuPont Water and Protection is a global leader in creating water, shelter and safety solutions for a more sustainable world; enabling its customers to win through unique capabilities, global scale and iconic brands including Kevlar®, Nomex®, Tyvek®, Corian® Design, GreatStuff™, Styrofoam™, and FilmTec™.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at http://www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

# # #

8/9/22

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

Share article on social media or email:

Smartlink Health Exceeds 100 EHR Integrations for Manifest MedEx and Reduces the Average Integration Time by 70%


In addition to drastically decreasing the time it takes to complete an integration…we’ve also been able to reduce our operational overhead related to ongoing support and maintenance. Jason Buckner, CIO, Manifest MedEx

Today Smartlink Health announced that Manifest MedEx, California’s largest nonprofit health data network, has joined the ranks of Smartlink Health partners that have exceeded 100 Electronic Health Record (EHR) integrations. Since switching to Smartlink’s Integration Platform as a Service (iPaaS), Smartlink Data Connector, Manifest MedEx has cut the average time it takes to complete a clinic EHR integration by more than 70%.

In addition to the current integration project that is ongoing, Smartlink is also beginning work on a new integration project to extract deeper patient data needed by insurers for performance measurement and risk adjustment (the Healthcare Effectiveness Data and Information Set, or HEDIS). For this project, Smartlink will extract EHR data that is not available through traditional methods of integration such as via API and HL7.

“We couldn’t be happier with our partnership with Smartlink”, said Manifest MedEx’s Chief Information Officer, Jason Buckner. “In addition to drastically decreasing the time it takes to complete an integration, we’ve significantly expanded the number of EHR brands that we can integrate with. We’ve also been able to reduce our operational overhead related to ongoing support and maintenance.”

Thus far, Smartlink has completed 115 integrations for Manifest MedEx that span twenty-seven different EHR brands, 75 of which were completed in just nine months. Depending on the EHR, integrations for Manifest MedEx are typically completed in a couple of days or weeks, with a large percentage being completed within a week.

“Manifest MedEx has been a great partner to work with and we’re very excited to reach such an important milestone with them,” said Ginny Mahaney, Smartlink’s Chief Commercial Officer. “Like many of our partners, Manifest MedEx understands that the data exposed by EHR vendors via traditional integration methods just isn’t enough to fully support performance measurement and risk adjustment. We’re looking forward to expanding our relationship and delivering the data needed to help move the needle on better care and patient outcomes.”

Smartlink Data Connector (SDC) leverages an IT system’s user interface (UI) to exchange data bi-directionally. It works with any operating environment (SaaS, hosted, on-premise), and can insert or extract virtually any type of data, including scheduling, documents, images, discrete data, and messages. With SDC, integrations that often take six to nine months can be completed in a matter of weeks, and without EHR vendor involvement.

About Manifest MedEx

As California’s leading nonprofit health data network, Manifest MedEx delivers real-time information to help healthcare providers and health plans care for millions of patients every day. Together, we are transforming the healthcare landscape across the state, supporting California as a leader in affordable, proactive, and compassionate medical care. For more information, visit manifestmedex.org and follow us on Twitter at @ManifestMedEx and on LinkedIn at linkedin.com/company/manifest-medex.

About Smartlink Health Solutions

Smartlink Health Solutions is an innovator in healthcare IT and is focused on helping organizations solve two of their biggest challenges – the transition from reactive care delivery to proactive care delivery, and the quest for seamless data sharing across the care continuum. Smartlink’s integration Platform-as-a-Service enables rapid, affordable integration between healthcare IT and other systems via the user interface. Smartlink’s care management platform supports Medicare’s value-based fee for service programs and helps employers proactively protect employees from COVID-19. For more information, visit SmartlinkHealth.com.

Share article on social media or email:



Aspirion Achieves HITRUST Risk-based, 2-year Certification to Further Mitigate Risk in Third-Party Privacy, Security, and Compliance


News Image

“Our HITRUST certification once again differentiates us from our competitors and further illustrates that we will spare no expense in safely achieving uncommon collection performance for our clients.” –Jason Erdell, Chief Executive Officer at Aspirion

Aspirion, a Best-in-KLAS-rated leader in collecting US healthcare systems’ most complex reimbursements, has further expanded its leadership position by earning Certified status for information security by HITRUST for its Compass and eCollections applications hosted at Microsoft Azure.

HITRUST Risk-based, 2-year (r2) Certified status demonstrates that the organization’s Compass and eCollections applications hosted at Microsoft Azure have met key regulations and industry-defined requirements and are appropriately managing risk. This achievement places Aspirion in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks, and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

“Health systems deserve a partner that takes safeguarding sensitive patient information as seriously as they do, ” said Jason Erdell, Chief Executive Officer at Aspirion. “Our HITRUST certification once again differentiates us from our competitors and further illustrates that we will spare no expense in safely achieving uncommon collection performance for our clients.”

As a healthcare RCM leader, the HITRUST status further illustrates the unparalleled strengths of Aspirion’s broad array of proprietary AI-enabled solutions centered on complex claims, revenue integrity, and Medicaid services.

“Aspirion’s HITRUST Risk-based, 2-year (r2) certification is a powerful illustration of our continuous commitment to prioritizing data security across our industry-leading technology platform,” said Steven Filchock, Chief Technology Officer at Aspirion. “This certification is the result of our Aspirion mindset to go above and beyond previously accepted norms.”

“The HITRUST Assurance Program is the most rigorous available, consisting of a multitude of quality assurance checks, both automated and manual,” said Bimal Sheth, Executive Vice President, Standards Development & Assurance Operations, HITRUST. “The fact that Aspirion has achieved HITRUST Risk-based, 2-year Certification attests to the high quality of their information risk management and compliance program.”

To learn more about HITRUST CSF Certified status, visit the website here. For more information about Aspirion, visit here or follow on LinkedIn here.

About Aspirion

Aspirion, headquartered in Columbus, Ga., helps hospitals and physicians recover otherwise lost claims revenue from Motor Vehicle Accidents, Workers’ Compensation, Veterans Affairs, and TRICARE as well as out-of-state Medicaid, Medicaid eligibility, underpayments, and denials. Aspirion’s experienced team of healthcare, legal, and technical professionals combined with industry-leading technology platforms help ensure that providers receive their Complex RCM revenue so that providers, hospitals, and their staff can focus on patient care. The Company serves over 160 clients across 45 states, including 40% of the largest health systems in the U.S.

Share article on social media or email:

Survey on Sexual Health Among Women with Lung Cancer Reveals High Levels of Sexual Dysfunction


Dr. Narjust Florez, Dana Farber Cancer Institute in Boston.

“Sexual health should be integrated into thoracic oncology care, and further research is necessary to develop tailored interventions for patients with lung cancer,” Dr. Florez said.

Survey on Sexual Health Among Women with Lung Cancer Reveals High Levels of Sexual Dysfunction

(Vienna, Austria)–According to survey data reported today, sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity. The survey results from the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study were reported today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

“Most of the data regarding sexual dysfunction in patients with lung cancer precedes the approval of targeted therapy and immune checkpoint inhibitors,” said Dr. Narjust Florez, Dana Farber Cancer Institute in Boston. “We report the results of the SHAWL study, the largest study to date evaluating sexual dysfunction in women with lung cancer.”

The SHAWL study is a cross-sectional, IRB-approved, global survey study administered via the GO2 Foundation Lung Cancer Registry. The study utilized the Patient-Reported Outcomes Measurement Information System (PROMIS®) Sexual Function and Satisfaction Measures (a validated questionnaire) to evaluate sexual health. Study participants were recruited between June 2020 to June 2021.

Eligibility criteria included age over 18 years, self-identifying as a woman, fluency in English, and an LC diagnosis. Participants were asked about sexual activity pre-lung cancer diagnosis and over the “past 30 days” prior to completing the survey.

Of the 249 women who completed the survey. Most (64%) patients had stage IV lung cancer and 107 (45%) were receiving targeted therapy with 93 of those (87%) taking the medication for more than six months. At the time of survey completion, 78 participants (33%) were taking anti-depressants and 34 (14%) were taking beta-blockers. Within the prior 30 days, 127 (53%) participants had sexual activity with themselves or someone else. 183 (77%) participants reported little to no interest in sexual activity, and 159 (67%) stated rarely or never wanting to have sexual activity. The most common reasons negatively affecting participants’ satisfaction with their sex life (very much to somewhat) included fatigue 95 (40%), feeling sad/unhappy 66 (28%), issues with their partners 52 (22%), and shortness of breath 36 (15%).

Out of the 127 participants that had sexual activity in the last 30 days, 75 (59%) reported significant issues with vaginal dryness and 63 (26%) vaginal pain/discomfort during sexual activity. When comparing before and after lung cancer diagnosis, marked differences were noted in decreased sexual desire/interest (15% vs. 31%, p less than 0.001) and vaginal pain/discomfort (13% vs. 43%, p less than 0.001).

Dr. Florez reported that fatigue, feeling sad/unhappy and shortness of breath were the most common reasons negatively affecting participants’ sex life satisfaction and shows the differences with other cancers and the need to use lung cancer-specific data while treating patients with lung cancer and sexual dysfunction.

“Sexual health should be integrated into thoracic oncology care, and further research is necessary to develop tailored interventions for patients with lung cancer,” Dr. Florez said.

About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2022.iaslc.org/.

Share article on social media or email:

Meridian Clinical Research Appoints Chief Medical Officer, Adds New Medical Director


“With our combined efforts, expansive network, and veteran expertise, Meridian will continue to be a leader for traditional clinical trials, and for research programs involving novel technologies and digitalized research conduct.” – Shishir Khetan, MD

Meridian Clinical Research, a leading multi-specialty investigative research site network, has promoted Brandon Essink, MD, CPI, to Chief Medical Officer, and promoted Shishir Khetan, MD, to Medical Director. Both physicians will continue to serve as Principal Investigators for clinical trials at Meridian. The doctors will support new and existing principal investigators across Meridian’s therapeutically diverse network, which has grown to 35 sites.

Dr. Essink has served as a Meridian Principal Investigator since 2003. Throughout this tenure, he has become a renowned investigator for pioneering vaccine research programs. In 2020, Dr. Essink led weekly meetings with vaccine developers participating in the Operation Warp Speed (OWS) program and collaborating with the National Institutes of Health (NIH) and Biomedical Advanced Research and Development Authority (BARDA). He served as one of three co-lead principal investigators for Moderna’s Phase 3 COVID-19 vaccine trial for mRNA-1273, was appointed to the trial’s data and safety monitoring board (DSMB), and co-authored the trial’s primary publication in the New England Journal of Medicine.

Dr. Khetan joined Meridian as a Principal Investigator in 2018. In 2020, he enrolled more than 500 participants into Moderna’s Phase 3 COVID-19 vaccine trial (mRNA-1273), and, under his guidance, Meridian’s Rockville site continues to be a top enroller for vaccine research programs. In 2022, Dr. Khetan was also named President of Rockville Internal Medicine Group.

Dr. Khetan is also a Regional Medical Director and Virtual Medical Director for Privia Medical Group, and serves on the Privia Health and Privia Quality Network Board of Governors.

Together, Dr. Essink and Dr. Khetan will oversee clinical practices and support Meridian’s strategic development team to enhance physician engagement and oversight. The doctors currently serve as a resource for other Meridian investigators during trial conduct, and meet and support the training of all new physicians joining Meridian as research partners. The two will also provide protocol design and authoring support for research programs.

Dr. Essink said he and Dr. Khetan will focus on ensuring Meridian’s research capabilities continue to be best-in-class for Sponsors and CROs. “As the company adds sites and therapeutic specialties, Dr. Khetan and I will strengthen the clinical practices that drive responsive, accurate trial conduct,” said Dr. Essink.

Dr. Khetan commented that, “Clinical research is entering a new frontier with decentralized trials and electronic source documentation. With our combined efforts, expansive network, and veteran expertise, Meridian will continue to be a leader for traditional clinical trials, and for research programs involving novel technologies and digitalized research conduct.”

Since opening in Omaha in 1999, Meridian has enrolled more than 85,000 patients in 3,400 clinical trials. To learn more about Meridian’s network and research capabilities, visit mcrmed.com/sponsors-and-cros.

Share article on social media or email:

Informed Consent Forms for Lung Cancer Clinical Trials May be a Barrier to Informed Trial Participation


Bellinda King-Kallimanis, PhD., Director of Patient-Focused Research at LUNGevity Foundation in Bethesda, Md.

Informed Consent Forms for Lung Cancer Clinical Trials May Be a Barrier to Informed Trial Participation

Informed consent forms are overwhelming for patients. They are written at a level that is too high for most patients, thus possibly impeding real informed consent, according to a report given today at the IASLC World Conference on Lung Cancer in Vienna.

The purpose of the informed consent form (ICF) is to outline risks and benefits of an interventional clinical trial to a patient. But most ICFs are written using scientific jargon, are long, and include extraneous information not pertinent to the patient (e.g., legalities of trial participation), according to Bellinda King-Kallimanis, PhD., Director of Patient-Focused Research at LUNGevity Foundation in Bethesda, Md.

King-Kallimanis and her colleagues conducted a multi-step project involving patients and caregivers, trialists, regulators, and clinical trial sponsors to streamline the informed consent process. After a thorough analysis of their findings, some key challenges emerged along with ideas for improving ICFs. One possible resolution strategy that patients supported would be to create a tri-fold template summarizing key points of the ICF that are relevant to patients, which can be used as an addendum to the ICF.

The first step included an audit of 20 ICFs guided by U.S. Department of Health and Human Services regulations for the protection of human subjects in research. The second step included focus groups and in-depth interviews with nine patients living with lung cancer to learn what information was critical when considering participation in a clinical trial using a hypothetical ICF to guide the conversation.

The 20 ICFs reviewed were from phases 1, 2, and 3 clinical trials covering predominantly non-small cell lung cancer — 60% were global trials. Most of the legally required CFR topics were covered. However, forms were long, ranging between 15-34 pages, with an average length of 21 pages. Readability varied by section but the average reading level across sections was 10th grade, whereas the average U.S, reading level is 8th grade.

The second step of the study was the qualitative research component in which participants were presented with a hypothetical ICF. Participants generally noted feeling “overwhelmed” by the hypothetical ICF. It was noted that “a lot of information was good” but that important information for deciding whether to participate was often too hard to find. When asked the intent of the forms, one participant noted “to cover their butts”. The idea of an addendum that provides a summary with reference to page numbers in the ICF for more details was well received by participants. The next phase of this work is to develop a tri-fold addendum and test it with patients and caregivers.

“While ICFs place greatest emphasis on trial procedures and risks, variations in ICF architecture and readability make it difficult for patients to make an informed decision to participate in a clinical trial,” King-Kallimanis reported. “Our study implications extend beyond lung cancer, highlighting key areas for improvements to the ICFs and providing a clear roadmap for developing a patient-centric addendum for ICFs in all cancer clinical trials.”

About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2022.iaslc.org/.

Share article on social media or email:

Commission for Case Manager Certification’s new board leadership affirms dedication to quality and case manager empowerment


News Image

The Commission for Case Manager Certification® announced its 2022.2023 Board officer slate today. As the first and largest nationally accredited organization providing case management and disability management specialist certification, the Commission advocates for professional growth and lifelong learning. It does so through research-based exams and continuing education credits while maintaining ethical standards to maximize consumer protection, scientific understanding and quality case management practice.

Teresa (Teri) Treiger, RN, MA, CCM, FABQAURP, will serve as chair of the 17-member volunteer board. She has been a certified case manager since 2001. With her background in case management, nursing, health care administration and care management, she deeply understands the vital role of CCMs in health care.

Treiger is the founder and principal at Ascent Care Management—providing private case management services, consulting and more. She is also an editor and featured columnist for Professional Case Management’s The Heartbeat of Case Management. In the past, she served as and National President of the Case Management Society of America and was a founding board member of the National Transitions of Care Coalition.

“Every day, I see my service as vitally connected to the mission, vision and value of certification,” Treiger said. “It’s bigger than me and today’s Commission, and even bigger than the 50,000+ board certified CCM and CDMS holders. We possess a legacy and pledge to advocate for professional case management excellence through certification and interrelated programs.

We have the privilege of upholding a commitment to consumer protection and quality case management practice, as well as being the keepers of case management ethical standards and behavior.”

In addition to Treiger, the Commission’s 2022.2023 officers are:

  • Chair-Elect: Ed Quick, MA, MBA, CDMS, Senior Manager of Global Leave and Time Away Programs for a large technology company;
  • Secretary: Patricia Nunez, MA, CRC, CDMS, CCM, Director, Claim Supply Management, CNA;
  • Treasurer: Anne Mercer, CIA, CFE, CFSA, Managing Director, Standards & Guidance, Institute of Internal Auditors; and
  • Immediate Past-Chair: Jared Young, Psy.D., CAADC, LCSW, CCM, Founder & Practitioner, Private Practice.

The Commission also added two new board members:

  • Rebecca Fisco, CDMS, Manager, Vocational Services and Operations, The Ohio State University; and
  • R. Keith Franklin, PhD, LPC-S, LCDC, ACS, CEAP, CCM, EAP Psychologist, Department of Defense

“In the turmoil of the last few years and with the health care landscape continuing to evolve, case managers continue to play a vital role as patient advocates,” said MaryBeth Kurland, MPA, CAE, ICE-CCP, Commission CEO. “We’re focused on the whole-person and the professional community, encouraging CCMs, CDMS and members of the care team to care for themselves and clients while pursuing lifelong learning.”

“Our Commissioners bring a deep understanding of case management best practices derived from their wealth of experience,” Kurland added. “Their expertise informs and helps support the quality of our credentialing programs and maintains the certifications as the gold standard, while empowering practitioners to reach their highest potential by developing themselves personally and professionally.”

###

About the Commission for Case Manager Certification:

The Commission for Case Manager Certification is the first and largest nationally accredited case management certification organization, credentialing more than 50,000 professional case managers and disability management specialists. The Commission is a nonprofit, volunteer organization that oversees the process of case manager certification with its CCM® and CDMS® credentials. Offering an extensive portfolio of certification and professional advancement activities, the Commission is the most active and prestigious certification organization supporting the practices of case management and disability management. For more information, visit http://www.ccmcertification.org and http://www.cdms.org, connect with the Commission on Facebook or follow us on Twitter @CCM_Cert.

Share article on social media or email:

GrandCare Systems® and LADD Reveal Proven ROI and Cost Savings for Smart Home Technology in Disability Group Housing


Assistive Technology ROI for Disability Providers

Assistive Technology ROI for Disability Providers

“Our partnership with GrandCare Systems® along with our innovative business model has improved resident independence, family satisfaction and saved a lot of money. Staff are available when people need them, which is liberating both for staff and for the people receiving services.”

Individuals with developmental disabilities often face increased barriers to independent living. Disability support providers, just like other in-home care organizations, are experiencing serious staff shortages, rising costs of services, and a growing number of people requiring these services.

GrandCare Systems®, makers of touchscreen-based remote monitoring/support technology, and LADD, Inc., a non-profit agency empowering adults with developmental disabilities (DD) announced groundbreaking results from a Xavier University study. Researchers at Xavier set out to measure “occupational performance” (the ability to do everyday tasks without help), resident satisfaction, and the cost of care in the new smart home setting. The results were remarkable including a 75% reduction in in-person support hours.

In fall of 2020, four residents moved into LADD’s newly constructed “Heidt Smart Home” which was outfitted with groundbreaking enabling technologies. In addition to security, smart home and accessibility technologies, and wearables, GrandCare touchscreens were placed in every room throughout the house. These touchscreens support residents in daily tasks, cognitive assists, medication adherence, family connection and one touch video support. GrandCare’s activity and telehealth sensors prompted remote caregivers to proactively support and intervene in resident care exactly when and where help was needed.

One of the metrics used in the study was success in Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (IADLs). These include tasks such as: bathing, dressing, and eating, but also financial management, shopping and meal preparation. The technologies “allowed for residents to perform more of their ADLs and IADLs successfully, with less supervision.” Not only that, but technology-assisted care brought “increases in participants’ self-ratings of performance and satisfaction.”

The men in the smart home were able to do more things independently, for themselves, which led to higher feelings of self-worth and satisfaction.

“This system has the power to transform disabilities services and improve lives across the country,” said Brian Hart, Chief Operating Officer at LADD, Inc. “Our partnership with GrandCare Systems® along with our innovative business model has improved resident independence, family satisfaction and saved a lot of money. Staff are available when people need them, which is liberating both for staff and for the people receiving services.”

“Our partnership with LADD has been incredibly rewarding,” said GrandCare CEO, Laura Mitchell. “Together we have created a model and technology application that is specifically customized and catered to the developmental disability population, their families and caregivers.”

The study also found that LADD was able to safely reduce direct caregiving hours by an astonishing 75% while improving outcomes. This had a profound impact on the cost of care. Prior to GrandCare and remote monitoring technologies, the cost of in-person supports was $5,260 per week. Supportive technologies slashed the total cost of support for the four residents by more than 50% to only $2,607 per week. That adds up to $137,941 per year. With these savings, LADD was able to pay off all of the smart home technology in less than a year, only 36.7 weeks.

The LADD smart living system is arguably the first and most innovative tech-enabled system in the disability marketplace. The results have been so overwhelmingly positive that LADD is currently building several more smart homes for clients with DD and is offering consulting services to other disability service providers seeking to replicate LADD’s business plan along with their carefully vetted technology solutions.

GrandCare and LADD will co-present a free webinar on Wednesday, August 17, at 1pm ET sharing insights, results of the study and lessons learned in the past three years of working together. All are welcome to attend, however, spots are limited and registration is required. Register for free here.

About GrandCare Systems®:

GrandCare is a large touchscreen hub with communication, cognitive assists and social engagement tools, including medication reminders, daily task lists, schedules, instructional videos and HIPAA compliant video chat options. Wireless telehealth and activity monitoring sensors can alert support staff if something needs extra attention. GrandCare has been serving the aging and disability industry since 2005 and with headquarters in Wisconsin and southern California.

Media Contact: LMC

Marketing & PR FIRM

LMC@LMCLLC.us

About LADD:

Guided by the belief that every person has ability and value, LADD empowers adults with developmental disabilities to live, work, and connect. Founded in 1975, the Cincinnati non-profit now supports more than 650 individuals through housing, employment and meaningful community engagement programs. Learn more at https://laddinc.org.

Media Contact: Nyketa Gaffney

Communications Manager

ngaffney@laddinc.org

Share article on social media or email:

Kayal Rheumatology Center Is Dedicated To Easing Every Patient’s Chronic Pain


Kayal Rheumatology Center

Kayal Rheumatology Center

The experts at Kayal Rheumatology Center are dedicated to minimizing and treating their patient’s chronic pain conditions.

Their elite team of skilled and experienced specialists will be with you every step of the way on your chronic pain journey.

Their team of expert rheumatologists includes reviewed and approved NJ Top Doc, Irina Raklyar, MD, FACR, Rajesh Pandey, MD and Alan Zalkowitz, MD.

These reviewed and approved NJ Top Docs focus on treatments that stop inflammation, relieve pain and other symptoms, prevent joint and organ damage, improve mobility and limit long-term complications.

Dr. Rajesh K. Pandey is a born-and-raised New Englander who received his bachelor’s degree in biology and psychology from the University of Massachusetts at Amherst in 1998. He then worked at the prestigious Massachusetts General Hospital Department of Dermatology and Wellman Laboratory of Photomedicine until entering Ross University Medical School, where he graduated with an MD in 2006. Dr. Pandey completed his residency training at the University of Medicine and Dentistry of New Jersey (UMDNJ) in 2009. Dr. Pandey then completed his fellowship in rheumatology at Albany Medical Center in 2012 under the mentorship of world leaders in rheumatology.

Dr. Pandey entered private practice in Bergen County in 2012 and has since remained dedicated to the community. He has performed thousands of ultrasound-guided injections including carpal tunnel and knee injections. He also remains current with the latest advances in rheumatology and osteoporosis treatments.

Dr. Pandey is board certified in internal medicine, specializing in rheumatology. He is a member of the American College of Rheumatology.

Dr. Raklyar has been serving patients in northern New Jersey for over 10 years as a board-certified rheumatologist, specializing in arthritis and autoimmune diseases. She prides herself in staying current and offering modern, evidence-based medicine. She has advanced her practice with experience in musculoskeletal ultrasound for both diagnosis and therapeutic intervention.

Dr. Zalkowitz is the Chief of Rheumatology & Internal Medicine and is board-certified in both fields. He has over 40 years of experience and notably started the Arthritis and Rheumatology Fellowship at Mount Sinai Medical Center in NYC in addition to starting the Lupus Foundation of New Jersey. He has been recognized as one of the foremost rheumatologists on the East Coast.

To learn more about the NJ Top Docs at Kayal Rheumatology Center, please visit: https://njtopdocs.com/nj-doctors/kayalrheumatology/

—

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email: